间歇性内分泌治疗联合近距离放疗在局限性前列腺癌治疗中的应用  

Application of intermittent hormonal therapy combined with brachytherapy in the treatment of patients with localized prostate cancer

作　　者：吕玉良[1] 张再高[1] 田峰[1] 

机构地区：[1]江苏省连云港市东方医院泌尿外科,江苏连云港222042

出　　处：《实用临床医药杂志》2016年第21期59-61,65,共4页Journal of Clinical Medicine in Practice

摘　　要：目的探讨间歇性内分泌治疗(IHT)联合近距离放疗在局限性前列腺癌治疗中的应用价值。方法将82例局限性前列腺癌患者随机分为观察组和对照组,各41例。对照组给予IHT,观察组给予IHT联合125I粒子植入近距离放疗,比较2组治疗情况、生化无进展生存期(BPFS)、5年无事件生存率及5年总生存率。结果观察组治疗有效率为97.6%,显著高于对照组的80.5%(P<0.05)。观察组中位BPFS为33.9个月,显著长于对照组的21.2个月(P<0.05)。观察组5年无事件生存率和5年总生存率显著高于对照组,差异有统计学意义(P<0.01)。结论 IHT联合125I粒子植入近距离放疗治疗局限性前列腺癌患者的有效率优于单纯IHT,延长BPFS,且不良反应可耐受。Objective To explore the application value of intermittent hormonal therapy（ IHT） combined with brachytherapy in the treatment of patients with localized prostate cancer.Methods Eighty- two patients with localized prostate cancer were randomly divided into observation group（ n = 41） and control group（ n = 41）. The patients in control group were treated with IHT,while those in observation group were given IHT combined with125 I seed implantation brachytherapy.Treatment conditions,biochemical progression-free survival（ BPFS）,5-year non-event survival rate and 5- year overall survival rate were compared between two groups. Results The response rate was97. 6% in observation group,which was significantly higher than 80. 5% in control group（ P〈0. 05）. The median BPFS were 33. 6 months in observation group,which was significantly longer than 21. 2 months in control group（ P〈0. 05）. Both 5- year non- event survival rate and 5- year overall survival rate in observation group were significantly higher than those in control group（ P〈0. 01）. Conclusion For patients with localized prostate cancer,IHT combined with125 I seed implantation brachytherapy is superior to IHT alone in response rate and BPFS,and adverse reactions can be tolerable.

关 键 词：前列腺癌 间歇性内分泌治疗 近距离放疗 125I粒子植入 生存率 

分 类 号：R737.25[医药卫生—肿瘤]